Search Results
Sep 01, 2026, 09:11 ET BioViva Announces U.S. Patent for Klotho Gene Therapy Targeting Age-Related Cognitive Decline
The patent covers the use of gene therapy to deliver human Klotho (KL) and telomerase reverse transcriptase (hTERT) for the treatment or prevention of age-related cognitive decline, including conditions associated with
More news about: BioViva USA Inc.
Aug 31, 2026, 01:30 ET WORQ Receives Frost & Sullivan's 2026 Malaysian Flexible Workspace Competitive Strategy Leadership Recognition for Excellence in Flexible Workspace Strategy
to facilities management and day-to-day administration. The company also places strong emphasis on wellbeing, community, and engagement. WORQ Well at KL Eco City, Malaysia's first and only coworking space to receive the WELL Coworking Rating, exemplifies this approach through an experience-led workplace
More news about: Frost & Sullivan
Aug 31, 2026, 01:30 ET WORQ Receives Frost & Sullivan's 2026 Malaysian Flexible Workspace Competitive Strategy Leadership Recognition for Excellence in Flexible Workspace Strategy
to facilities management and day-to-day administration. The company also places strong emphasis on wellbeing, community, and engagement. WORQ Well at KL Eco City, Malaysia's first and only coworking space to receive the WELL Coworking Rating, exemplifies this approach through an experience-led workplace
More news about: Frost & Sullivan
Aug 19, 2026, 07:00 ET Jocasta Signs UCSF Licensing Agreement to Advance α-klotho for Managing Cognitive Impairment
neurodegenerative-induced dementia. Jocasta's foundational data demonstrates the critical role of α-klotho in health and disease – from human genetics (effect of KL mutations) to robust cognitive enhancement in healthy rats, rodent disease models and non-human primates. Backed by this body of evidence, JN-0413 will
More news about: Jocasta Neuroscience, Inc.
Aug 13, 2026, 16:30 ET METALLA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 AND PROVIDES ASSET UPDATES
growing scale of both the South and North Zone systems. KLDC also stated that winter drilling at KL West and KL South came in under budgeted, as a result KLDC has added an additional 5,000 m of drilling at KL South, bringing the total program up to 30,000 m.Metalla holds a 1.0% NSR royalty on the
More news about: Metalla Royalty & Streaming Ltd.
Aug 03, 2026, 07:45 ET Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
mutation in pancreatic cancer. Semin Oncol. 2021;48(1):10-18. doi:10.1053/j.seminoncol.2021.02.003Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel). 2016;8(4):45. Published 2016 Apr 18. doi:10.3390/cancers8040045Muller
More news about: Eli Lilly and Company
Jul 30, 2026, 05:09 ET NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
Jul 30, 2026, 05:06 ET 邁向晚期TNBC一線治療！蘆康沙妥珠單抗(sac-TMT)第六項NDA獲受理
腫瘤細胞，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及台灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥
More news about: 科倫博泰
Jul 15, 2026, 08:54 ET Dao by Dorsett AMTD Singapore Honoured with Tripadvisor Travellers' Choice 2026, Recognised Among the Top 10% of Properties Worldwide
Singapore: Dao by Dorsett AMTD Hotel in Singapore- United Kingdom: AMTD Dao by Dorsett Hornsey Hotel in London- Malaysia: AMTD IDEA KL Hotel in Kuala Lumpur- United States: AMTD IDEA Tribeca Hotel in New YorkAbout AMTD GroupAMTD Group is a conglomerate
More news about: AMTD IDEA Group; AMTD Digital Inc.; The Generation Essentials Group
Jul 14, 2026, 22:14 ET $HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote--CCRN, EQH, AXTA, and CZNL
CCRN) related to its sale to KL Criss Cross Intermediate, LLC. Under the terms of the proposed transaction Cross Country shareholders are expected to receive $13.25 per share in cash.ACT
More news about: Monteverde & Associates PC
Jul 14, 2026, 20:00 ET 全球首個ADC+IO對比免疫聯合化療一線治療PD-L1陰性非鱗狀NSCLC III期研究達到主要終點，蘆康沙妥珠單抗聯合帕博利珠單抗有望重塑治療格局
，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及台灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(
More news about: 科倫博泰
Jul 14, 2026, 19:30 ET Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
Jul 09, 2026, 14:08 ET Gas Holders Market to Reach USD 113 Million by 2035 as Hydrogen Storage and Renewable Energy Transition Drive Global Demand
units.Gas holders of capacity below 100 KL form the bulk of decentralized gas storage and small-scale biogas business, widely used in farm biogas programs, household uses, and small-scale food industries. Meanwhile, units with capacities above 1,000 KL form the core topic in industrial gaseous
More news about: Future Market Insights
Jul 07, 2026, 21:32 ET TGE在打造全球尚乘品牌酒店網絡方面取得重大進展
Hotel)新加坡：新加坡帝盛尚乘道酒店(Dao by Dorsett AMTD Singapore)英國：倫敦的尚乘霍恩西Dao by Dorsett酒店(AMTD Dao by Dorsett Hornsey)馬來西亞：吉隆坡的尚乘國際KL酒店(AMTD IDEA KL Hotel)美國：紐約的尚乘國際翠貝卡酒店(AMTD IDEA Tribeca Hotel)這些酒店資產的所有權將進行重組，劃歸至尚乘酒店集團名下持有，形成一個統一的、全球互聯互通的酒店服務平台。依托尚乘多元化媒體娛樂業務及更廣泛的生態體
More news about: AMTD IDEA Group; AMTD Digital Inc.; The Generation Essentials Group
Jul 07, 2026, 09:19 ET TGE Highlights Significant Progress in Building Its Global AMTD-Branded Hotels Network
SARSingapore: Dao by Dorsett AMTD Hotel in SingaporeUnited Kingdom: AMTD Dao by Dorsett Hornsey Hotel in LondonMalaysia: AMTD IDEA KL Hotel in Kuala LumpurUnited States: AMTD IDEA Tribeca Hotel in New YorkThe ownership of these hotel properties will be restructured
More news about: AMTD IDEA Group; AMTD Digital Inc.; The Generation Essentials Group
Jul 06, 2026, 10:03 ET Argosy Charts a New Route with K&L Freight Acquisition
download multimedia:https://www.prnewswire.com/news-releases/argosy-charts-a-new-route-with-kl-freight-acquisition-302818399.htmlSOURCE
More news about: Argosy Private Equity
Jun 25, 2026, 23:06 ET 尚乘發布2026年上半年營收正面預警，得益於通過成功收購4家酒店，旗下酒店業務板塊貢獻增長
Group（簡稱「TGE」，紐交所：TGE；倫交所：TGE）聯合（上述公司統稱「該集團」或「尚乘」）宣布，今年內該集團已成功完成四家酒店的收購，分別為珀斯麗思卡爾頓酒店(The Ritz-Carlton)、紐約尚乘國際翠貝卡酒店(AMTD IDEA Tribeca Hotel)、倫敦尚乘霍恩西Dao by Dorsett酒店(AMTD Dao by Dorsett Hornsey)、吉隆坡尚乘國際KL酒店(AMTD IDEA KL Hotel)，總對價約為2.07億美元。 近期完成的這四起收購，連同2019年收購的香港富薈尚乘上環酒店(iclub AMTD Sheung Wan Hotel)和新加坡帝盛尚乘道酒店(Dao by Dorsett AMTD Singapore)，讓該集團的酒店資產組合發展至成熟階
More news about: AMTD IDEA Group; AMTD Digital Inc.; The Generation Essentials Group
Jun 25, 2026, 10:02 ET AMTD Announces Positive Revenue Alert in 1H 2026, attributable to increased contributions from the Hospitality Arm through Successful Acquisitions of 4 Hotels
completed the acquisitions of four hotels: The Ritz-Carlton, Perth; AMTD IDEA Tribeca Hotel in New York; AMTD Dao by Dorsett Hornsey in London; and AMTD IDEA KL Hotel in Kuala Lumpur, for a total consideration of approximately US$207 million. These four recent acquisitions, together with iclub AMTD Sheung
More news about: AMTD IDEA Group; AMTD Digital Inc.; The Generation Essentials Group
Jun 23, 2026, 16:21 ET Veeva opkøber Copli og lancerer Veeva Falcon MLR for at fremskynde gennemgangen af indhold
registrere dig til det kommende webinar den 9. juli kl. 10. ET eller besøg FalconMLR.veeva.com.Om Veeva SystemsVeeva
More news about: Veeva Systems
Jun 23, 2026, 09:05 ET New Published Five-Year Data Shows Exceptional Results for Knee Osteoarthritis Patients Treated with the MISHA® Knee System
System (n=81) over high tibial osteotomy (n=81). The 81 patients that received MISHA were followed out to five years with early to severe medial knee OA (KL 1-4). The average MISHA patient had knee OA symptoms for over four years, and all patients failed non-surgical treatments prior to their MISHA surgery. Key
More news about: Moximed
Jun 22, 2026, 09:06 ET 蘆康沙妥珠單抗聯合奧希替尼一線治療EGFR突變NSCLC轉化研究成果刊發於《Cancer Cell》
公司擁有自主知識產權的新型人源化TROP2 ADC，適應症覆蓋NSCLC、乳腺癌(BC)、胃癌(GC)、婦科腫瘤、泌尿生殖系統腫瘤等多種晚期實體瘤。sac-TMT采用獨特雙功能連接子開發而成：一端與抗TROP2單抗沙妥珠單抗不可逆結合，另一端可在溶酶體內發生pH依賴性裂解，釋放貝洛替康衍生物拓撲異構酶I抑制劑載荷，從而最大限度地將毒性載荷遞送至腫瘤細胞，藥物抗體比(DAR)達7.4。sac-TMT通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面TROP2，經腫瘤細胞內吞後，在細胞內釋放毒性載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致
More news about: 科倫博泰
Jun 22, 2026, 01:45 ET Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable,
More news about: Kelun-Biotech
Jun 17, 2026, 13:50 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SUNE, NUVL, CCRN, and BGMS
CCRN) related to its sale to KL Criss Cross Intermediate, LLC. Under the terms of the proposed transaction Cross Country shareholders are expected to receive $13.25 per share in cash.ACT
More news about: Monteverde & Associates PC
Jun 16, 2026, 04:57 ET Wynn Returns as Official Host Partner of Asia's 50 Best Bars 2026 in Landmark 20th Anniversary Year
first session, followed by Honky Tonks Tavern and The Green Door.Time: 2pm – 5pmVenue: Wing Lei Bar, Wynn PalaceFROM KL WITH LOVE – Monday, July 27Three X Co (Kuala Lumpur) and Penrose (Kuala Lumpur) bring the energy and sophistication of Malaysia's
More news about: Wynn Resorts Macau
Jun 16, 2026, 04:41 ET Wynn Returns as Official Host Partner of Asia's 50 Best Bars 2026 in Landmark 20th Anniversary Year
session, followed by Honky Tonks Tavern and The Green Door.Time: 2pm – 5pmVenue: Wing Lei Bar, Wynn PalaceFROM KL WITH LOVE – Monday, July 27Three X Co (Kuala Lumpur) and Penrose (Kuala Lumpur) bring the energy and sophistication of Malaysia's
More news about: Wynn Resorts Macau